clinical trial · NCT03666715
A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
Janssen-Cilag Farmaceutica Ltda.·—·completed·n = 55
SchizophreniaOral Antipsychotics (OAPs)Paliperidone Palmitate 1-Month Formulation (PP1M)
brief summary
The purpose of this study is to investigate the mean number of schizophrenia-related hospital admissions, in adult participants with schizophrenia, occurred during 12 months before and 12 months after initiation of Paliperidone Palmitate 1-month formulation treatment.
started
Aug 7, 2018
primary completion
May 31, 2021
completion
May 31, 2021
last updated
Apr 27, 2025
official title
A Multicenter Retrospective Study to Analyse the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Patients With Schizophrenia in Portugal
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol